Biology of Autism — Clinician Guide

Clinical Framing

The Subgroup

Immune-derived autism — a mechanistically distinct, biomarker-definable subgroup

The immune-derived autism (IDA) cascade does not describe all autism. It describes a subgroup in which a multi-step biological cascade — originating in gut pH dysregulation and converging on SST-14 interneuron silencing — produces the ASD phenotype cluster.

The clinical utility of the cascade framework is not in providing a fixed protocol. It is in giving the heterogeneous symptom picture a coherent upstream structure — one that allows intervention to be sequenced logically rather than symptom by symptom across disconnected specialties.

The key identifiers for this subgroup: elevated inflammatory biomarkers, measurable methylation cycle disruption, and the characteristic clinical fingerprint that gains from peptide or behavioral interventions attenuate over time — the signature of a locked second messenger infrastructure.

Two-layer model. The AofA paper presents the IDA framework as a two-layer model: the convergent cascade mechanism (seven converging steps from gut pH to SST-14 silencing) and the constitutional susceptibility architecture (seven tipping points that determine who the cascade propagates in). The cascade explains the mechanism; the constitutional profile explains the selection. Most children exposed to the same founding conditions do not develop IDA because their constitutional profile at one or more tipping points provides sufficient headroom. A child presenting with IDA typically carries reduced headroom at multiple tipping points simultaneously: ATP4A/ATP4B proton pump variants, constitutively low DPP-IV, MTHFR C677T, KMO excitotoxic branch bias, reduced mitochondrial reserve, or HLA-mediated autoantibody susceptibility. This constitutional profile is both an explanatory tool and an emerging biomarker — Testable Prediction 7 of the model.

Important: This is a research-informed model for a biologically defined subgroup. It does not explain all autism. Large-scale prospective validation studies are needed. All clinical decisions require qualified medical oversight with direct knowledge of the individual patient. The two-layer model and constitutional susceptibility architecture are developed in full in The Anatomy of Autism .

The Central Question

Which domain is most upstream — and what order of support is most coherent?

Children with immune-derived autism characteristically present to multiple specialists simultaneously: gastroenterologist for GI dysfunction, sleep specialist for sleep architecture disruption, OT for sensory processing, speech therapist for communication. None of these presentations is wrong. All are real downstream expressions of the same upstream mechanism.

The cascade framework identifies these as parallel outputs of one biological failure — and locates which domain is driving the others rather than treating each domain as independently primary.

The Three-State Clinical Framework

Staging

How deeply are the SST-14 interneurons silenced?

The three-state framework identifies where along the SST-14 silencing spectrum a patient sits. States reflect the mechanism and depth of interneuron suppression — not behavioural severity, which is an imprecise proxy for biological state. A non-verbal child may be State 1 if cascade burden is primarily transcriptional; a higher-functioning child may be State 2 if metabolic exhaustion has accumulated. States are not mutually exclusive — the dominant state guides intervention priority.

State 1 — Most Reversible

Transcriptional suppression

Mechanism: Two independent mechanisms suppress SST-14 transcription simultaneously. Mechanism A: NF-κB outcompetes CREB for CBP (CREB-binding protein), the co-activator both require — redirecting CBP to the inflammatory transcriptional program while simultaneously recruiting HDAC enzymes to compact chromatin around the somatostatin gene promoter. Mechanism B: adenosine accumulation from CD26 blockade activates Gαi-coupled receptors, suppressing adenylyl cyclase, depleting cAMP, and preventing PKA-mediated CREB phosphorylation independently of Mechanism A. Both mechanisms operating simultaneously removes all compensatory routes. The interneuron is structurally and metabolically intact — recovery is primarily rate-limited by immune clearance.

Clinical pattern: Gains that plateau; rapid attenuation of improvement from novel interventions; elevated inflammatory markers on workup.

Key biomarkers: Elevated K:T ratio; cytokine elevation; autoantibody positive; L:P ratio normal (<20).

Primary intervention: Infrastructure repair + IMIG/IVIG for immune clearance and autoantibody reduction.

State 2 — Metabolic Exhaustion

Mitochondrial failure

Mechanism: Sustained quinolinic acid NMDA overactivation has depleted mitochondrial ATP. NAD⁺ consumption exceeds replacement. SAMe insufficiency has degraded mitochondrial membrane integrity through phosphatidylcholine depletion.

Clinical pattern: Disproportionate fatigue; low muscle tone; poor stamina; sleep that does not restore energy; constipation and GI dysmotility prominent.

Key biomarkers: Elevated K:T ratio; elevated L:P (>25); low plasma NAD⁺; elevated 8-isoprostane; elevated homocysteine.

Primary intervention: Infrastructure repair + IMIG/IVIG + NAD⁺ precursors + mitochondrial support + methylation restoration. Consider MSC trophic support.

State 3 — Structural Loss

Interneuron loss + A1 astrocyte polarisation

Mechanism: Partial SST-14 interneuron loss. Microglial A1 astrocyte-inducing signalling has withdrawn hevin/SPARCL1, BDNF, and synaptogenic support. A1 state reverses when inflammatory signals are removed (Liddelow et al., Nature 2017).

Clinical pattern: Long-standing severe presentation; regression during illness; limited response even to intensive intervention; low BDNF.

Key biomarkers: Elevated K:T ratio; low BDNF; elevated L:P; A1 markers elevated; reduced hevin/SPARCL1.

Primary intervention: Infrastructure repair + IMIG/IVIG + MSC trophic restoration (IGF-1, BDNF, A1→A2 shift).

Biomarker Panel

Laboratory Investigation

The mechanistically organised IDA biomarker panel

Two or more positive criteria constitute a strong signal for the immune-derived autism subgroup. The combination of K:T elevation + cytokine elevation + homocysteine elevation + autoantibody positivity is the core enrolment criterion for the biomarker-stratified trial framework.

Biomarker	Finding	Cascade mechanism	State
K:T ratio	↑ Elevated	IDO1 activation; tryptophan diversion; quinolinic acid production	All
Cytokine panel (IL-6, TNF-α, IL-1β)	↑ Two or more elevated	Active NF-κB inflammatory environment; IDO1 and CREB suppression drivers	All
Neural autoantibody panel	↑ Positive titres	SST-14 interneuron surface receptor jamming	State 1 primary
Plasma homocysteine	↑ Elevated with normal B12/folate	Adenosine rate-limiting methionine synthase; methylation cycle stall	All
Lactate:pyruvate ratio	↑ >25 = State 2 indicator	Mitochondrial dysfunction; calcium overload from quinolinic acid NMDA activation	States 2/3
Plasma NAD⁺	↓ Low	IDO1 overactivation consuming NAD⁺ faster than kynurenine pathway can replace it	State 2 primary
Plasma BDNF	↓ Low	A1 astrocyte polarisation withdrawing BDNF; CREB suppression reducing BDNF transcription	State 3 primary
RBC glutathione	↓ Depleted	Transsulfuration bottleneck from methylation failure; reduced antioxidant defence	All

Cascade Staging — Clinical Signals at Each Level

Systems Map

Reading the cascade as a clinical reasoning tool

The cascade has seven recognisable stages. Knowing where a patient sits identifies which biomarkers are most likely abnormal and which intervention domains have the highest leverage.

Stage	Clinical signals	Key resource
Founding conditions	C-section, formula feeding, recurrent strep, H. pylori, OCP zinc depletion, MTHFR variants, organophosphate exposure — often in birth and family history.	Molecular Origins
Pepsin failure + opioid peptides	Intense dairy/wheat selectivity; low plasma Phe/Tyr/Trp despite adequate diet; urinary casomorphin/gliadorphin positive; reduced DPP-IV activity.	Pepsin & Opioid Peptides
CD26 / methylation failure	Elevated homocysteine (normal B12/folate); joint hypermobility; fatigue disproportionate to activity; GSTP1 or MTRR variants; recurrent strep history; mercury exposure.	CD26 & Methylation
LPS / IDO1 / NF-κB	Elevated K:T ratio; cytokine elevation; elevated LPS-binding protein or zonulin; GI dysbiosis; IgG subclass abnormalities; infectious regression trigger.	Cascade Explained
SST-14 interneuron silencing	Positive autoantibody panel; elevated QUIN; elevated L:P; low NAD⁺. Pattern of gains with rapid attenuation — the clinical fingerprint of locked second messenger infrastructure.	Unlocking the Brake
Neuropeptide disruption	Social motivational deficit; modality-nonspecific sensory processing abnormalities; sleep architecture disruption (40–80%); constipation and delayed gastric emptying; motor coordination difficulties.	Cascade Explained
Self-reinforcing latch	No spontaneous improvement over extended periods; regression during illness; partial intervention response consistently followed by return to baseline; progressive narrowing of behavioural repertoire.	Metabolic Pathways

Six-Step Clinical Workflow

Screen for the IDA subgroup

Collect birth and feeding history, infectious history (recurrent strep especially), dietary pattern and food selectivity, family autoimmune history, maternal OCP use. Order: K:T ratio, cytokine panel, plasma homocysteine, neural autoantibody panel, RBC glutathione. Two or more positive criteria = IDA subgroup signal.

Stage the interneuron state

Add lactate:pyruvate ratio, plasma NAD⁺, plasma BDNF, and plasma quinolinic acid. Normal L:P + positive autoantibodies = State 1. Elevated L:P + low NAD⁺ = State 2. Low BDNF + elevated L:P = State 3 component. Dominant state guides intervention priority.

Identify upstream drivers still active

H. pylori testing; stool microbiome analysis; gut permeability (lactulose:mannitol or zonulin); urinary casomorphin/gliadorphin. Active upstream drivers must be addressed — infrastructure repair works against a persistent signal if the source is not reduced.

Begin infrastructure repair immediately

Sulforaphane, NAC+glycine, magnesium, and tributyrin can begin while full results are pending. These reduce inflammatory and oxidative burden across all three states without requiring state-specific determination. See Unlocking the Brake for sequencing.

Consider immune evaluation for IMIG candidacy

Order: IgG subclass panel, NK cell and lymphocyte subset panel, specific polysaccharide antibody titres. The IDA biomarker combination with positive autoantibodies and cytokine elevation identifies the IMIG-responsive subgroup. Refer to a clinician experienced in neuroimmune dysregulation. See Immunoglobulin Therapy.

Monitor biomarkers, not just behaviour

K:T ratio trending down, homocysteine falling, cytokine panel normalising — biomarker response is evidence the upstream cascade is being addressed. Behavioural improvement follows biomarker improvement with a lag of weeks to months depending on state. Repeat the core panel at 3 and 6 months.

When to Refer

Referral Guidance

Clinicians experienced in this model — who to involve and when

The cascade framework requires multi-disciplinary involvement. No single specialist covers the full clinical picture — the value of the framework is in coordinating across disciplines around a shared mechanistic understanding. The following referral signals and specialist types are most relevant.

Referral trigger	Specialist type	Notes
Positive autoantibody panel, IgG subclass abnormalities, recurrent infections, IMIG/IVIG candidacy evaluation	Paediatric or adult neuroimmunologist	Essential for IMIG/IVIG candidacy assessment. Request specific polysaccharide antibody titres, NK cell panel, and Cunningham Panel if PANS/PANDAS is suspected.
Elevated homocysteine, low SAMe:SAH, MTHFR/AHCY variants, folate receptor antibodies, methylation cycle failure	Functional or integrative medicine physician experienced in methylation protocols	MAPS (Medical Academy of Pediatric Special Needs) physicians are specifically trained in the metabolic and immune frameworks relevant to this cascade. Seek practitioners familiar with James et al. 2004/2006 methylation biomarker protocols.
GI dysmotility, constipation, suspected H. pylori, dysbiosis, gut permeability, secretin failure pattern	Paediatric gastroenterologist experienced with ASD-associated GI dysfunction	H. pylori testing and eradication, motility assessment, and gut microbiome analysis are within standard GI scope. Explain the pepsin/pH mechanism — most GI physicians will recognise the clinical picture even if they haven't encountered the cascade framing.
Elevated L:P ratio, low NAD⁺, mitochondrial dysfunction markers, hypotonia, fatigue disproportionate to activity	Metabolic/mitochondrial specialist or clinical biochemist	State 2 and State 3 patients with elevated L:P ratios warrant specialist metabolic assessment to rule out primary mitochondrial disease and to guide the NAD⁺ and phosphatidylcholine restoration protocol safely.
Acute-onset regression, OCD, tics, or neuropsychiatric symptoms following infection — suspected PANS/PANDAS	PANS/PANDAS specialist or child and adolescent psychiatrist with neuroimmune experience	Cunningham Panel, ASO titre, anti-DNase B, streptococcal culture, and complement levels. IMIG candidacy evaluation is time-sensitive in acute PANS — the window for intervention before structural changes accumulate is narrower than in the chronic ASD presentation.
MSC therapy consideration — State 2 not responding to immune clearance, or State 3 with low BDNF and structural loss	Cell therapy specialist at an academic medical centre conducting ASD MSC trials	MSC therapy for ASD is experimental. Only engage through registered clinical trials or academic research programmes with IRB oversight. Avoid commercial cell therapy clinics offering MSC without formal trial infrastructure.

Where to Go Next

Working Paper

The Anatomy of Autism — two-layer model and constitutional susceptibility

The complete mechanistic foundation: convergent cascade, seven tipping points, Mechanism A/B dual CREB suppression, ten testable predictions. Under expert review prior to journal submission.

Open The Anatomy of Autism →

Intervention Logic

Three-state framework + full intervention table

Compounds mapped to cascade nodes with evidence tiers, dosing ranges, and sequencing logic.

Open Intervention Logic →

Immunoglobulin Therapy

IVIG and IMIG — evidence, mechanism, and trial design

Three-state table, adjunct protocol, IMIG vs MSC comparison, and the trial that needs to happen.

Open Immunoglobulin Therapy →

Testing Strategy

Full biomarker panel and ordering guidance

Which tests identify the subgroup, stage the cascade, and monitor treatment response.

Open Testing Strategy →

Metabolic Pathways

Full mechanistic reference — P1 through P9

The molecular detail behind every cascade node — for clinicians who want the biochemistry behind the clinical picture.

Open Metabolic Pathways →